Searched for
BIOPHARMA GROWTH
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- Piyush Goyal meets Ernst & Young CEO, discusses India's role in global supply chainsUnion Minister Piyush Goyal said he held a meeting with Janet Truncale, Global Chair and CEO of EY, to discuss India's growing role in glob...
- Japanese biotech developing tooth-regrowing drug raises $5.3 million to advance human trialsToregem BioPharma has secured $5.3 million to advance its experimental tooth-regeneration drug, TRG035, into Phase II clinical trials. The ...
- India steers boat through a risky channel between war clouds and El NinoIndia faces a challenging global economic outlook for 2026-27. Geopolitical tensions and volatile oil prices are key concerns. However, Ind...
- Bernstein initiates coverage on 6 pharma stocks, cites 3 major tailwinds for healthcare sectorBernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...
- Biocon reports 63% YoY fall in Q4 profit, final dividend of Rs. 0.50 recommendedBiocon's fourth-quarter net profit saw a significant drop of 63 percent year-on-year. This decline was attributed to exceptional charges im...
- Biocon Q4 Results: Net profit down 57% at Rs 198.6 croreBiocon Ltd reported a 56.8% drop in Q4 net profit to Rs 198.6 crore, impacted by an Rs 80.4 crore exceptional item. Despite this, consolida...
- Moderna stocks: MRNA shares jump in US Stock market today after pharma giant surpasses Wall Street estimatesModerna had earlier posted a loss of $2.52 per share a year earlier, while analysts expected a loss of $3.96 per share.
- India Pharma 2026 event: Nadda lays out road map for India to take global pharma leadership roleIndia Pharma Conference: India is set to become a global leader in advanced medicines like biologics and biosimilars, Union Minister J P Na...
- Sun Pharma closes in on Organon buy, gets set for $12 billion binding bidSun Pharmaceutical Industries is nearing a $12 billion acquisition of Organon & Co, marking its most significant overseas expansion. Follow...
- Stocks in news: TCS, HDFC Bank, ITC Hotels, Hyundai India, Adani EnterprisesMarkets surged for the fourth consecutive session, buoyed by favorable geopolitical cues. Key stocks like TCS, HDFC Bank, ITC Hotels, Hyund...
- Budget 2026: Sitharaman launches 'Biopharma Shakti' with a Rs 10,000-crore bet to heal India, power manufacturingUnion Budget 2026: With the announcement of the 'Biopharma Shakti' initiative, India is gearing up to take the world stage in biopharmaceut...
- Budget 2026: Sitharaman proposes Rs 10,000-crore Biopharma Shakti scheme to boost biopharma manufacturingThe proposed fund aims to position India as a global biopharma manufacturing hub
- Budget 2026: Sitharaman’s six-point plan to propel India’s next growth phaseUnion Budget 2026: Finance Minister Nirmala Sitharaman has presented a six-point plan to boost India's economy. The strategy prioritizes ma...
- India emerging as favourable destination to conduct global clinical trials: ReportThe joint report by the USA India Chamber of Commerce & PwC India titled, “Clinical Trial opportunities in India” which will be released at...
- Dr. Reddy's inks pact with Singapore firm Prestige BioPharma to commercialise Trastuzumab biosimilar in select countriesHyderabad, Dec 9- Prestige BioPharma Ltd, a Singapore-based firm and Dr. Reddy's Laboratories Ltd., on Thursday announced that the two comp...
- Biocon to invest 10% of biopharma revenues on R&D next fiscalThe Bengaluru-based company has spent Rs 47 crore on R&D in the third quarter of this fiscal, an increase of 124 per cent over the correspo...
- Biocon: Parting ways with Pfizer may hurt company in long runWith the snapping of ties, the Indian biotech company has limited options for growth of its insulin especially in regulated markets.
- Intas Biopharma in talks with Japanese co for outlicensingIntas Biopharmaceutical Ltd, a group company of the Rs 1,600-crore Intas Pharmaceuticals Ltd, would soon enter into an out-licensing and su...
Load More
